ENTRY       D11556                      Drug
NAME        Idecabtagene vicleucel (USAN);
            Abecma (TN)
PRODUCT     ABECMA (Celgene Corporation)
REMARK      ATC code: L01XL07
            Product: D11556<US>
EFFICACY    Antineoplastic, Anti-BCMA CAR-T cell
  DISEASE   Multiple myeloma [DS:H00010]
  TYPE      Cellular therapy product, CAR-T cell therapy
TARGET      TNFRSF17 (BCMA, CD269) [HSA:608] [KO:K05153]
  PATHWAY   hsa04060(608)  Cytokine-cytokine receptor interaction
            hsa04672(608)  Intestinal immune network for IgA production
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L01 ANTINEOPLASTIC AGENTS
               L01X OTHER ANTINEOPLASTIC AGENTS
                L01XL Antineoplastic cell and gene therapy
                 L01XL07 Idecabtagene vicleucel
                  D11556  Idecabtagene vicleucel (USAN) &lt;US&gt;
            Target-based classification of drugs [BR:br08310]
             Cytokines and receptors
              Cytokine receptors
               Tumor necrosis factor receptors
                TNFRSF17 (BCMA, CD269)
                 D11556  Idecabtagene vicleucel (USAN) &lt;US&gt;
            New drug approvals in the USA [br08319.html]
             Cellular and gene therapy products
              D11556
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D11556
             Cellular and gene therapy products
              D11556
            New drug approvals in Japan [br08318.html]
             Cellular and gene therapy products
              D11556
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D11556
DBLINKS     PubChem: 384585532
///
